6628 fundamentals

Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company, which engages in discovery, research, development, and manufacturing of differentiated antibody therapies in therapeutic areas with high unmet medical needs. It focuses on oncology, nephrology, and bone diseases. The firm also develops Immune Tolerance Breaking technology platform to build a diversified and risk-balanced pipeline of antibodies. The company was founded on August 20, 2010 and is headquartered in Suzhou, China.